Developmental regression, the loss of previously acquired language and social skills during the second year of life, affects 20–40% of children with autism spectrum disorder (ASD), yet its metabolic underpinnings remain poorly defined. Existing metabolomics studies have focused on amino acid and acylcarnitine alterations, leaving the eicosanoid, sphingolipid, and glycoconjugate axes largely unexamined. Plasma from 25 children with regressive ASD (REG+), 27 with non-regressive ASD (REG−), and 21 typically developing controls (aged 2–6 years) was profiled using untargeted Q-TOF LC/MS (Agilent 6530, ESI+ mode, 100–1700 m/z). From 6657 detected features, a stepwise curation pipeline combining statistical significance (raw p < 0.05 with Benjamini–Hochberg FDR correction, q < 0.05; FC > 1.5), analytical plausibility, endogenous origin verification, and literature-based directional alignment yielded a prioritized set of 14 annotated metabolic features. Exploratory PLS-DA (Partial Least-Squares Discriminant Analysis) visualization showed separation among the three groups within the present dataset; however, diagnostic or predictive performance was not evaluated. The 14-feature panel clustered along four biochemical axes. A feature putatively annotated as prostaglandin E3 (PGE3) showed a 7.13-fold reduction in REG+ versus controls (1.58-fold in REG−; FC REG+/REG− = 4.52). N-Acetylneuraminosyl-(α2-6)lactosamine and aspartylglycosamine were decreased 4.44-fold and 5.42-fold in REG+, respectively, with regression-specific amplification (FC REG+/REG− > 2.0). Six sphingolipid–myelin metabolites showed coordinated biosynthetic depletion and catabolic elevation in both ASD groups without regression specificity. DHEA-S exhibited the largest subgroup differential (FC REG+/REG− = 8.89), with paradoxically greater depletion in the non-regressive group. This exploratory study identified several plasma metabolic features showing abundance differences among children with REG+, REG−, and typically developing controls. These findings are hypothesis-generating and require confirmation using authenticated standards, targeted quantitative methods, and independently recruited cohorts before any diagnostic, predictive, or therapeutic relevance can be established.
Cihan Aslan, O. Kaplan, N. Yalçın et al.· International Journal of Mol...· 0 citations
This narrative review provides a comprehensive synthesis of mortality rates and associated risk factors among individuals with autism spectrum disorder (ASD) across the lifespan. Following a search across PubMed, Scopus, and Google Scholar, 31 peer-reviewed studies were identified for synthesis. The findings consistently demonstrate that individuals with ASD experience significantly higher mortality rates compared to neurotypical controls. Analysis shows a distinct developmental shift: in childhood and adolescence, external causes are predominant, with accidents—particularly drowning—accounting for a substantial portion of fatalities, estimated between 70% and 90% in some reports. In contrast, adult mortality is increasingly driven by natural causes. The evidence indicates a reduced life expectancy, with some studies reporting average ages of death as low as 36 years, depending on comorbid conditions. Furthermore, standardized mortality ratios appear notably higher in individuals with co-occurring intellectual disabilities and epilepsy, with some cohorts showing risks several times higher than the general population. A substantial proportion of ASD-related mortality is potentially preventable through targeted safety training, early metabolic screening, and ASD-friendly healthcare practices. Addressing communication barriers and sensory sensitivities in clinical settings is essential for early diagnosis and effective management of chronic conditions to reduce the mortality gap.
Buket Kılıç, Dilek Ünal, Cihan Aslan et al.· Turkish Journal of Pediatric...· 0 citations